Lista de obras - Karla M. Eggert - Dominio Público Uruguay

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

artículo científico publicado en 2016

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

artículo científico publicado en 2016

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

scientific article published on 11 April 2011

Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine

artículo científico publicado en 2006

Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice

artículo científico publicado en 2009

Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing

artículo científico publicado en 2007

Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologists

artículo científico publicado en 2009

Brain monoamine systems in multiple system atrophy: a positron emission tomography study.

artículo científico publicado en 2012

Clinical risk-benefit assessment of dopamine agonists

artículo científico publicado en 2008

Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications

artículo científico publicado en 2008

Cost effectiveness of pharmacotherapies in early Parkinson's disease

artículo científico publicado en 2008

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy

artículo científico publicado en 2011

Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study

artículo científico publicado en 2010

Costs of Parkinson's disease in eastern Europe: a Czech cohort study

artículo científico publicado en 2009

Costs of drug treatment in Parkinson's disease

artículo científico publicado en 1998

Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany).

artículo científico publicado en 2007

Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease

artículo científico publicado en 2005

Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease

artículo científico publicado en 2011

Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes

artículo científico publicado en 2013

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

artículo científico publicado en 2009

Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease

artículo científico publicado en 2012

Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial ⬇️

artículo científico publicado el 7 de diciembre de 2010

Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach

artículo científico publicado en 2016

Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage

artículo científico publicado en 2016

Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease

artículo científico publicado en 2007

Frequency and treatment of depressive symptoms in a Parkinson's disease registry

artículo científico publicado en 2008

Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro

artículo científico publicado en 1999

Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study ⬇️

artículo científico publicado el 9 de febrero de 2011

Health-related quality of life in multiple system atrophy

artículo científico publicado en 2006

Health-related quality of life in multiple system atrophy and progressive supranuclear palsy

artículo científico publicado en 2011

In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.

artículo científico publicado en 2010

In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy

artículo científico publicado en 2009

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

artículo científico publicado en 2005

Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole

scholarly article published in Clinical Neuropharmacology

Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes.

artículo científico publicado en 2012

Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany

artículo científico publicado en 2010

MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation

artículo científico publicado en 2013

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).

artículo científico publicado en 2010

Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).

artículo científico publicado en 2007

Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy

artículo científico publicado en 2009

Parkinson's disease: cost-of-illness in an outpatient cohort

artículo científico publicado en 2010

Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test

artículo científico publicado en 2011

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease

artículo científico publicado en 2011

Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?

artículo científico publicado en 2010

Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

artículo científico publicado en 2006

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

artículo científico publicado en 2017

Rationale for transdermal drug administration in Alzheimer disease

artículo científico publicado en 2007

Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.

artículo científico publicado en 2008

Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease

scientific article published on 01 April 2010

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study

artículo científico publicado en 2010

Role of dopamine transporter SPECT for the practitioner and the general neurologist ⬇️

artículo científico publicado el 1 de octubre de 2003

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

scientific article published on 02 July 2019

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

artículo científico publicado en 2010

Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study

artículo científico publicado en 2014

Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review

artículo científico publicado en 2013

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

artículo científico publicado en 2008

The Competence Network Parkinson (CNP)

artículo científico

The European Multiple System Atrophy-Study Group (EMSA-SG).

artículo científico publicado en 2005

The GEPARD Data Collection Model – Protected Data Collection for the Gene Bank Parkinson's Disease Germany of the Competence Network on Parkinson's Disease (Datenerfassung in GEPARD – Die geschützte Datensammlung der Genbank Parkinson'sche Krank

artículo científico publicado en 2007

The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease

artículo científico publicado en 2008

Trends in resource utilization for Parkinson's disease in Germany

artículo científico publicado en 2010

Lista de obras de Karla M. Eggert

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine

Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice

Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing

Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologists

Brain monoamine systems in multiple system atrophy: a positron emission tomography study.

Clinical risk-benefit assessment of dopamine agonists

Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications

Cost effectiveness of pharmacotherapies in early Parkinson's disease

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy

Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study

Costs of Parkinson's disease in eastern Europe: a Czech cohort study

Costs of drug treatment in Parkinson's disease

Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany).

Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease

Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease

Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease

Does the clinical practice guideline on Parkinson’s disease change health outcomes? A cluster randomized controlled trial ⬇️

Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach

Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage

Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease

Frequency and treatment of depressive symptoms in a Parkinson's disease registry

Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro

Health-related quality of life and its determinants in Parkinson’s disease: Results of an Italian cohort study ⬇️

Health-related quality of life in multiple system atrophy

Health-related quality of life in multiple system atrophy and progressive supranuclear palsy

In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.

In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole

Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes.

Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany

MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).

Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).

Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy

Parkinson's disease: cost-of-illness in an outpatient cohort

Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease

Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?

Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Rationale for transdermal drug administration in Alzheimer disease

Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease.

Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease

Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study

Role of dopamine transporter SPECT for the practitioner and the general neurologist ⬇️

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study

Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

The Competence Network Parkinson (CNP)

The European Multiple System Atrophy-Study Group (EMSA-SG).

The GEPARD Data Collection Model – Protected Data Collection for the Gene Bank Parkinson's Disease Germany of the Competence Network on Parkinson's Disease (Datenerfassung in GEPARD – Die geschützte Datensammlung der Genbank Parkinson'sche Krank

The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease

Trends in resource utilization for Parkinson's disease in Germany